The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation

Platelets

Volumn 19, Issue 5, 2008, Pages 359-364

  Ruef, Johannes ^a   Kuehnl, Peter ^b   Meinertz, Thomas ^b   Merten, Michael ^b  

^a Red Cross Hospital Cardiology Center   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Atherosclerosis; Complement system; Platelet leukocyte aggregation; Properdin

Indexed keywords

CD11B ANTIGEN; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PROPERDIN;

ARTICLE; ATHEROSCLEROSIS; COMPLEMENT SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE AGGREGATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE;

ADENOSINE DIPHOSPHATE; ADULT; ANTIGENS, CD11B; ATHEROSCLEROSIS; BLOOD PLATELETS; CELL ADHESION; CELL AGGREGATION; COMPLEMENT PATHWAY, ALTERNATIVE; HUMANS; LEUKOCYTES; P-SELECTIN; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPERDIN;

EID: 51849116822     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100802105040     Document Type: Article

References (42)

1. Entman ML, Ballantyne CM. Asscociation of neutrophil with platelet aggregates in unstable angina: Should we alter therapy. Circulation 1996;94:1206-1208.
2. Konstantopoulos K, Grotta JC, Sils C, Wu KK, Hellums JD. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 1995;74:1329-1334.
3. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: A mechanism for recurrent disease?. J Am Coll Cardiol 1996;28:345-353.
4. Konstantopoulos K, Neelamegham S, Burns AR, Hentzen E, Kansas GS, Snapp KR, Berg EL, Hellums JD, Smith CW, McIntire LV, Simon SI. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998;98:873-882.
5. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000;102:1931-1936.
6. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996;88:146-157.
7. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997;100:2085-2093.
8. Langer HF, Daub K, Braun G, Schönberger T, May AE, Schaller M, Stein GM, Stellos K, Bueltmann A, Siegel-Axel D. et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol 2007;27:1463-1470.
9. Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C. Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost 2007;97:965-973.
10. Seifert PS, Hugo F, Tranum-Jensen J, Zähriger U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990;172:547-557.
11. Oksjoki R, Kovanen PT, Mäyränpää MI, Laine P, Blom AM, Meri S, Pentikäinen MO. Complement regulation in human atherosclerotic coronary lesions: Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis 2007;192:40-48.
12. Laine P, Pentikäinen MO, Würzner R, Penttilä A, Paavonen T, Meri S, Kovanen PT. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 2002;90:404-408.
13. Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem 2006;281:2128-2132.
14. Wirthmueller U, Dewald B, Thelen M, Schäfer MK, Stover C, Whaley K, North J, Eggleton P, Reid KB, Schwaeble WJ. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol 1997;158:4444-4451.
15. Bongrazio M, Pries AR, Zakrzewicz A. The endothelium as physiological source of properdin: Role of wall shear stress. Mol Immunol 2003;39:669-675.
16. Merten M, Beythien C, Gutensohn K, Kühnl P, Meinertz T. Thiagarajan PSulfatides activate platelets through P-selectin and enhance platelet and platelet-leukocyte aggregation. Arterioscler Thromb Vasc Biol 2005;25:258-263.
17. Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: A subgroup analysis from the GUSTO V and FASTER trials. J Thromb Thrombolysis 2002;14:197-203.
18. Moser M, Bertram U, Peter K, Bode C, Ruef J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 2003;41:586-592.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
20. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
21. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: Bridging thrombosis and inflammation. Circulation 2002;105:2130-2132.
22. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in avascular injury model. Blood 1997;89:1270-1278.
23. Elalamy I, Chakroun T, Gerotziafas GT, Petropoulou A, Robert F, Karroum A, Elgrably F, Samama MM, Hatmi M. Circulating platelet-leukocyte aggregates: A marker of microvascular injury in diabetic patients. Thromb Res 2008;121:843-848.
24. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, Michelson AD. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
25. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002;105:2130-2132.
26. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL 3rd, Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001;38:1002-1006.
27. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996;97:1525-1534.
28. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, Sticherling C, Meinl C, May A, Schömig A. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95:2387-2394.
29. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, Marathe GK, McIntyre TM, Zimmerman GA, Prescott SM. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005;111:633-642.
30. Abou-Saleh H, Théorêt JF, Yacoub D, Merhi Y. Neutrophil P-selectin-glycoprotein-ligand-1 binding to platelet P-selectin enhances metalloproteinase 2 secretion and platelet-neutrophil aggregation. Thromb Haemost 2005;94:1230-1235.
31. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
32. Chakraborti T, Mandal A, Mandal M, Das S, Chakraborti S. Complement activation in heart diseases. Role of oxidants. Cell Signal 2000;12:607-617.
33. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994;34:17-40.
34. Theroux P, Martel C. Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol 2006;22(Suppl. B):18B-24B.
35. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 2007;179:2600-2608.
36. Fijen CA, Bogaard R, Schipper M, Mannens M, Schlesinger M, Nordin FG, Dankert J, Daha MR, Sjoholm AG, Truedsson L, Kuijper EJ. Properdin deficiency: Molecular basis and disease association. Mol Immunol 1999;36:863-867.
37. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992;359:848-851.
38. Evangelista V, Manarini S, Sideri R, Rotondo S, Martelli N, Piccoli A, Totani L, Piccardoni P, Vestweber D, de Gaetano G. et al. Platelet/ polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: Role of PSGL-1 as a signaling molecule. Blood 1999;93:876-885.
39. Barnard MR, Linden MD, Frelinger AL 3rd, Li Y, Fox ML, Furman MI, Michelson AD. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005;3:2563-2570.
40. Li N, Hu H, Lindqvist M, Wikström-Jonsson E, Goodall AH, Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000;20:2702-2708.
41. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, et al. COMMA Investigators. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-1190.
42. Gupta-Bansal R, Parent JB, Brunden KR. Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies. Mol Immunol 2000;37:191-201.